BioWorld

A three-armed activator of natural killer cells against head and neck squamous cell carcinoma

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...
The American Journal of Managed Care

Optimizing Radiation in Head and Neck Cancer: Minimizing Adverse Effects

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and ...
Healio

Adjuvant nivolumab improves DFS in high-risk head and neck cancer

Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...
ascopubs.org

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer Newly diagnosed patients with cT2-4N0-2M0 HNC were ...
ascopubs.org

Induction chemotherapy using gemcitabine and cisplatin followed by hypofractionated radiotherapy in advanced head and neck squamous cell carcinoma.

Feasibility and efficacy of oral 5-FU in combination with pembrolizumab and cisplatin as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma: A prospective observational ...
Cure Today

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
Healio

Combination immunotherapy better than single agent in head, neck cancer

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...